CTX310 Delivers 52.5% Sustained LDL Reduction at One Year in 15-Patient Phase 1 Trial

The trial tested escalating doses of CTX310, an in vivo CRISPR-Cas9 therapy targeting hepatic ANGPTL3, in patients with refractory hyperlipidemia. Pre-treatment with steroids and antihistamines preceded the one-time infusion; lipid panels and safety labs were tracked to month 12. Highest-dose participants showed durable ANGPTL3 silencing that translated into roughly 50% average reductions in both LDL and triglycerides, with no treatment-related serious adverse events recorded.

These results extend earlier two-month data and align with human genetics showing ANGPTL3 loss-of-function variants lower LDL and triglycerides without apparent major penalties. Unlike PCSK9 monoclonal antibodies or inclisiran, which require repeated dosing, CTX310 offers a potential one-and-done alternative. However, the small sample and short follow-up leave open questions about off-target edits and rare late toxicities that only larger, longer trials can resolve.

Future Phase 2/3 studies must enroll broader populations, incorporate cardiovascular outcome endpoints, and apply rigorous long-term genomic surveillance per FDA gene-editing guidance. If durability and safety hold, CTX310 could shift treatment paradigms from chronic pharmacotherapy toward single-intervention genetic correction for lipid disorders.